The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Related articles in The JI
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leung, W.
Right arrow Articles by Handgretinger, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leung, W.
Right arrow Articles by Handgretinger, R.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Leukemia, Childhood
The Journal of Immunology, 2004, 172: 644-650.
Copyright © 2004 by The American Association of Immunologists

Determinants of Antileukemia Effects of Allogeneic NK Cells 1

Wing Leung2,*,{ddagger}, Rekha Iyengar*, Victoria Turner{dagger}, Peter Lang§, Peter Bader§, Paul Conn{dagger}, Dietrich Niethammer§ and Rupert Handgretinger*,{ddagger}

Departments of * Hematology-Oncology and {dagger} Pathology, St. Jude Children’s Research Hospital, and {ddagger} Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN 38105; and § Children’s University Hospital, Tuebingen, Germany

In HLA-nonidentical bone marrow transplantation, we studied the characteristics of donor NK cells, recipient leukemia cells, and the cytokine environment that predict the antileukemia effects of allogeneic NK cells. We found that the risk of relapse in pediatric patients with hematologic malignancies was best predicted by a model taking into consideration the presence of inhibitory killer cell Ig-like receptors (KIRs) on the donor’s NK cells and the absence of corresponding KIR ligand in the recipient’s HLA repertoire (a receptor-ligand model). The risk of relapse was prognosticated less precisely by the Perugia donor-recipient KIR ligand-ligand mismatch model or by a natural cytotoxicity model. In contrast to the ligand-ligand model, we found that the new receptor-ligand model was accurate when analysis was applied to patients with lymphoid malignancy. These findings corroborate our observations that the recipient’s KIR repertoire, which was derived from highly purified, HLA-disparate CD34+ cells, resumed a donor-specific pattern within 3 mo of transplantation, but did not correlate evidently with the donor or recipient ligand repertoire. In an in vitro assay and an in vivo mouse model, human NK cell cytotoxicity toward human leukemia cells with 11q23 chromosomal rearrangement increased with the number of receptor-ligand mismatch pairs or prestimulation with IL-12 and IL-18. These findings provide new insights into the determinants of antileukemia effects of allogeneic NK cells and therapeutic strategies.


Related articles in The JI:

IN THIS ISSUE

The JI 2004 172: 1-2. [Full Text]  



This article has been cited by other articles:


Home page
BloodHome page
M. Stern, L. Ruggeri, A. Mancusi, M. E. Bernardo, C. de Angelis, C. Bucher, F. Locatelli, F. Aversa, and A. Velardi
Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor
Blood, October 1, 2008; 112(7): 2990 - 2995.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Stern, L. Ruggeri, M. Capanni, A. Mancusi, and A. Velardi
Human leukocyte antigens A23, A24, and A32 but not A25 are ligands for KIR3DL1
Blood, August 1, 2008; 112(3): 708 - 710.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Shi, G. J. Tricot, T. K. Garg, P. A. Malaviarachchi, S. M. Szmania, R. E. Kellum, B. Storrie, A. Mulder, J. D. Shaughnessy Jr, B. Barlogie, et al.
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma
Blood, February 1, 2008; 111(3): 1309 - 1317.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Diermayr, H. Himmelreich, B. Durovic, A. Mathys-Schneeberger, U. Siegler, U. Langenkamp, J. Hofsteenge, A. Gratwohl, A. Tichelli, M. Paluszewska, et al.
NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities
Blood, February 1, 2008; 111(3): 1428 - 1436.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. H. Chewning, C. N. Gudme, K. C. Hsu, A. Selvakumar, and B. Dupont
KIR2DS1-Positive NK Cells Mediate Alloresponse against the C2 HLA-KIR Ligand Group In Vitro
J. Immunol., July 15, 2007; 179(2): 854 - 868.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. Ruggeri, A. Mancusi, M. Capanni, E. Urbani, A. Carotti, T. Aloisi, M. Stern, D. Pende, K. Perruccio, E. Burchielli, et al.
Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.
Blood, July 1, 2007; 110(1): 433 - 440.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. S. Miller, S. Cooley, P. Parham, S. S. Farag, M. R. Verneris, K. L. McQueen, L. A. Guethlein, E. A. Trachtenberg, M. Haagenson, M. M. Horowitz, et al.
Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT
Blood, June 1, 2007; 109(11): 5058 - 5061.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. C. Fischer, H. Ottinger, S. Ferencik, M. Sribar, M. Punzel, D. W. Beelen, M. A. Schwan, H. Grosse-Wilde, P. Wernet, and M. Uhrberg
Relevance of C1 and C2 Epitopes for Hemopoietic Stem Cell Transplantation: Role for Sequential Acquisition of HLA-C-Specific Inhibitory Killer Ig-Like Receptor
J. Immunol., March 15, 2007; 178(6): 3918 - 3923.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Fujii, J. D. Trudeau, D. T. Teachey, J. D. Fish, S. A. Grupp, K. R. Schultz, and G. S. D. Reid
In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides
Blood, March 1, 2007; 109(5): 2008 - 2013.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Mullally and J. Ritz
Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation
Blood, February 15, 2007; 109(4): 1355 - 1362.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. Triplett, R. Handgretinger, C.-H. Pui, and W. Leung
KIR-incompatible hematopoietic-cell transplantation for poor prognosis infant acute lymphoblastic leukemia
Blood, February 1, 2006; 107(3): 1238 - 1239.
[Full Text] [PDF]


Home page
BloodHome page
M. Thomas, A. Gessner, H.-P. Vornlocher, P. Hadwiger, J. Greil, and O. Heidenreich
Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells
Blood, November 15, 2005; 106(10): 3559 - 3566.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. Imai, S. Iwamoto, and D. Campana
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells
Blood, July 1, 2005; 106(1): 376 - 383.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. C. Hsu, C. A. Keever-Taylor, A. Wilton, C. Pinto, G. Heller, K. Arkun, R. J. O'Reilly, M. M. Horowitz, and B. Dupont
Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes
Blood, June 15, 2005; 105(12): 4878 - 4884.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
W. Leung, R. Iyengar, B. Triplett, V. Turner, F. G. Behm, M. S. Holladay, J. Houston, and R. Handgretinger
Comparison of Killer Ig-Like Receptor Genotyping and Phenotyping for Selection of Allogeneic Blood Stem Cell Donors
J. Immunol., May 15, 2005; 174(10): 6540 - 6545.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. Pende, G. M. Spaggiari, S. Marcenaro, S. Martini, P. Rivera, A. Capobianco, M. Falco, E. Lanino, I. Pierri, R. Zambello, et al.
Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112)
Blood, March 1, 2005; 105(5): 2066 - 2073.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.